The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Next Thursday (21st). They will have a good idea well before than I suspect. Next Wednesday??
This dip may be the lowest it goes........... for years!!
Moab.
If I had metastasized cancer (spread, or in the blood supply trying to re-seed) and I had for example an Illumina CtDNA test so the clinician could decide what treatment I should have I would want it to be as accurate as possible. The CtDNA test is to find actionable DNA variants. These are usually found by analysing DNA fragments of dead cells which naturally and up in blood plasma before being excreted. Some of these fragments are from the cancer tumour. Some treatments can TARGET these variants (therefore the cancer) slowing down the spread, possibly stopping it. Angle have shown that sometimes there are STILL actionable DNA variants in circulating cancer cells WHEN NONE ARE FOUND in the standard CtDNA test!!!!!!! Therfore Angle are suggesting ALL the Companies IN THE WORLD that already offer CtDNA analysis of the DNA fragments in blood plasma ALSO offer the same analysis of the circulating cancer cells. Clearly if a circulating cancer cell is STILL in the blood supply and it has actionable DNA variants that might be TARGETED by treatment it is rather important, to say the least!!
Clearly the stock market totally fails at the moment to appreciate this!!
Once Angle get the firrst Molecular analysis Co. on board this will massively change IMHO.
All IMHO.
Looks like the market has decided they are way undervalued.
Moab.
Please filter my posts. I have no interest at all in anything you say.
I find it totally astonishing that Molecular analysis Co's in the World, including Illumina Inc. of USA, seemed to be totally unaware that DNA sequencing CtDNA does NOT give the full picture of a patients cancer that has metastasized. Angle's RNS's dated 4th Jan and 22nd Jan show that also DNA sequencing LIVE circulating tumour cells (that Angles's Parsortix machine can catch in a matter of hours) can sometimes find actionable DNA variants in the cct's! Actionable DNA variants NOT FOUND in the CtDNA! These actionable DNA variants can be targeted for treatment by ****some treatments currently available****. Therefore clearly some patients with actionable DNA in their cancer have, and are still being missed.
Illumina and the other Co's in this field really need to sort this out.
- I'm sure Angle Plc will be willing to discuss ways forward with this.
All IMHO.
Ikhan1284.
"It's totally luck 😹 I will buy 50 million shares and see what happens".
======================
I'm waiting to see this.
This! LOL!
Hello.
Big rise for IAG, no news I can find????
One of these Molecular analysis Co's has simply got to offer this soon, even as an optional extra. It could save lives don't forget. DNA sequencing CtDNA does NOT give the full picture as to what actionable DNA varients there are in a patient. See Angle's RNS's dated 4th Jan and 22nd Jan..
First of all I find it difficult to believe a Company like Illumina, valued on NASDAQ at over $5 BILLION was unaware that analysing (DNA sequencing) circulating tumour cells (cct's), can give IMPORTANT additional information over and above the standard CtDNA analysis they offer. Surely the knew already? Note they do not seem to have a product to catch cct's as Angle and a few other co's do. Hmm. It's safe to say they do now as of 4th January, see Angles RNS announcement in which they actually used an Illumina product to get the results. Also they mention they were talking to Illumina (and others) about the results. I suspect Illumina and other Molecular analysis Co's will soon be asked some awkward questions as to why they either did not know, or why they have suppressed it...............................
I know one thing. If I had cancer that had spread and found out my clinician could have got more information but some large Co's could have helped but they were more concerned about profit I would not be happy.
All IMHO.
One of these Molecular analysis Co's has simply got to offer this soon, even as an optional extra. It could save lives don't forget. DNA sequencing CtDNA does NOT give the full picture as to what actionable DNA varients there are in a patient. See Angle's RNS's dated 4th Jan and 22nd Jan.
First of all I find it difficult to believe a Company like Illumina, valued on NASDAQ at over $5 BILLION was unaware that analysing (DNA sequencing) circulating tumour cells (cct's), can give IMPORTANT additional information over and above the standard CtDNA analysis they offer. Surely the knew already? Note they do not seem to have a product to catch cct's as Angle and a few other co's do. Hmm. It's safe to say they do now as of 4th January, see Angles RNS announcement in which they actually used an Illumina product to get the results. Also they mention they were talking to Illumina (and others) about the results. I suspect Illumina and other Molecular analysis Co's will soon be asked some awkward questions as to why they either did not know, or why they have suppressed it...............................
I know one thing. If I had cancer that had spread and found out my clinician could have got more information but some large Co's could have helped but they were more concerned about profit I would not be happy.
All IMHO.
Surprised if Oil Co's with wells in Alaska are interested. Clearly if 88E do get a decent flow result the value of their prospect acreage woud be hundreds of millions IMHO.
All IMHO.
or is someone taking the ****? lol!
LOL!
LOL!
LOL!
You say:
"Because for $250,000 they have nothing to lose. They havent made any commitment beyond one pilot study. Newland of course positioned this completely differently, trailing some huge deal with a major international pharma...its one bloody pilot study Andrew!".
===================================
Fevertreeman.
Clearly you have an axe to grind with Angle Plc. A top 100 Japanese Co. evaluating a drug that has a budget of $2 billion................. pull the other one!! LOL!!
When they got the FDA approval for using their Parsortix machine with breast cancer to catch circulating tumour cells from a standard blood sample for testing (e.g for HER-2 status) they envisaged the machines selling very well and clearly that did not happen. That was a huge disappointment and the reason the sp fell from £1.60 at it's peak to under 10p in December 2023. I believe one of the main reasons was the Co's Angle expected to buy the machines needed to invest in developing their ***own assays*** in order to actually carry out the tests on the cct's. This further cost along with the cost of the machines combined with changing from how they were used to getting the cct's (even if not as good as Parsortix) was a huge drag on sales. But Angle have since changed their business model. The bottom line is they do have a patented remarkable machine that can filter out LIVE circulating tumour cells (cct's) from a standard blood sample. 99% of there cells are LIVE (other methods often kill the cells) so it is simply not possible to get a better cct to test. Not possible. They have now developed their own assays (that they offer to sell with the machines) and they are using them to offer their own labs services to the World, demonstrating how the machines can be used. As far as potential markets go the one Eisai Inc. contract (involving just one of their cancer drug trials) could end up multi million if the trial progresses to stage 4. Just the ability to monitor the HER-2 status of a persons cancer before, during and after treatment is simply worth a fortune>>>>>>>>>>>>>>>
Regarding JUST HER-2:-
"3. HER2 Overexpression in Cancers
Most of the studies on HER2 have been carried out in breast cancer, after it was found to induce mammary carcinogenesis in vitro [14] and in vivo [15]. Amplification or overexpression of the HER2 gene occurs in approximately 15–30% of breast cancers [16]. With increasing understanding of HER2 biology, it has now been recognized that HER2 overexpression occurs in other forms of cancers also such as stomach, ovary, uterine serous endometrial carcinoma, colon, bladder, lung, uterine cervix, head and neck, and esophagus [17, 18]. Apart from its role in development of various cancers, it has also been intensely evaluated as a therapeutic target.
Basically Angle Plc could make a decent profit just from cancer drug trials for metastasized Breast cancer alone, which is a tiny, tiny fraction of the overall market IMHO.
All IMHO.
To monitor the patients HER-2 status in phase 2 of their antibody-drug conjugate, BB-1701 drug trial?
See RNS dated 2nd Jan 2024.
*******THIS IS THE QUESTION******* potential investors in Angle should ask themselves:-
https://en.wikipedia.org/wiki/Eisai_(company)
https://www.eisai.com/news/2023/news202330.html
To monitor the patients HER-2 status in phase 2 of their antibody-drug conjugate, BB-1701 drug trial?
See RNS dated 2nd Jan 2024.
*******THIS IS THE QUESTION******* potential investors in Angle should ask themselves:-
https://en.wikipedia.org/wiki/Eisai_(company)
Plus we know that just ONE contract could be worth millions to Angle.
Most likely and extremely significant news going forward:-
1. Other contracts along the lines of the one Eisia Inc, the top 100 Plc in Japan (see RNS dated 2nd Jan 2024). Employing ANGLE to use their HER2 assay to monitor a patients HER2 status during cancer treatment trials. Even the one with Eisia Inc might end up £ multi-million if the trial progresses to stage 2 and 3. Angle offer this service WORLD WIDE.............
2. A contract with ANY of the huge Molecular Analysis Companies that already offer cancer treatment guidance by analysing dead fragmants of cancer that can be found in a patients blood plasma (so from a standard blood sample).
Angle's Parsortix machine can catch circulating tumour cells (cct's) from the ***same standard blood sample***. Angle have discovered that analysing a patients cct's as well as the dead fragmants of cells found in the blood plasma gives ADDITIONAL important information about a persons cancer (see RNS dated 4th Jan).
- Existing Molecular Analysis Co's could offer Angle's Parsortix machine as an "extra-over" so the clinician can get the "full picture" for advising the best treatment moving forward.
- The Parsortix machine could be re-badged to show for instance "Illumina".............
- Any deal might commit Angle to NOT offer the machine to other Molecular Analysis Co's making their offerings inferior. The additional information simply does not exist in dead cancer fragments............................................
- Could be transformational for angle.
- Could simply be a buy out of Angle to offer the "Full picture" and to corner the market. Angle's tech could be incorporated in future machines the client offer making it a one process machine that gets 100% on the information available, the "Full Picture".
All IMHO.